AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30593513 — intervention group
Group type: COMPARATOR
Intervention: CNS metastasis observed at or after diagnosis
Number of subjects: 977
Study 30593513 — intervention group
Group type: COMPARATOR
Intervention: Quality of life
Number of subjects: 977
Study 30593542 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term physical activity (exercise within calculated training pulse for 8 months)
Number of subjects: 98
Study 30593776 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily aspirin use
Number of subjects: 1698
Study 30594245 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal function assessment using the gold standard methodology.
Number of subjects: 9
Study 30594474 — intervention group
Group type: EXPERIMENTAL
Intervention: LGE-CMR imaging
Number of subjects: 35
Study 30595180 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 233
Study 30595269 — intervention group
Group type: EXPERIMENTAL
Intervention: iFR-guided side-branch intervention
Number of subjects: 50
Study 30595681 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Osteoprotegerin (OPG) levels
Number of subjects: 0
Study 30595681 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-traditional, kidney-related cardiovascular risk factors
Number of subjects: 0
Study 30595681 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional cardiovascular risk factors
Number of subjects: 0
Study 30595963 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal surgery for OSB
Number of subjects: 21
Study 30596402 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine with rituximab, etoposide and carboplatin (T(R)EC)
Number of subjects: 0
Study 30596402 — intervention group
Group type: COMPARATOR
Intervention: (R)ICE regimen (rituximab, ifosfamide, carboplatin, etoposide)
Number of subjects: 0
Study 30596677 — intervention group
Group type: EXPERIMENTAL
Intervention: LivRelief Varicose Vein Cream
Number of subjects: 32
Study 30596809 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher exposures to regional NO2 (2-SD increase of 12.2 parts per billion)
Number of subjects: 3100
Study 30596809 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher exposures to acid vapor, EC, PM2.5, and non-freeway NOx
Number of subjects: 3100
Study 30596809 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher exposures to regional NO2, acid vapor, and EC
Number of subjects: 3100
Study 30596880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Number of subjects: 15
Study 30596880 — intervention group
Group type: COMPARATOR
Intervention: Afatinib
Number of subjects: 15
Study 30596880 — intervention group
Group type: COMPARATOR
Intervention: T-DM1
Number of subjects: 15
Study 30596882 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsivity
Number of subjects: 51368
Study 30596901 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted infection prevention and control (IPC) bundle including IPC training, text message reminders, alcohol hand rub, enhanced environmental cleaning, and weekly bathing with 2% chlorhexidine gluconate.
Number of subjects: 2669
Study 30596901 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted infection prevention and control (IPC) bundle
Number of subjects: 2669
Study 30596974 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal primary infection in the first trimester
Number of subjects: 255
Study 30596974 — intervention group
Group type: COMPARATOR
Intervention: Maternal primary infection in the second trimester
Number of subjects: 255
Study 30596974 — intervention group
Group type: COMPARATOR
Intervention: Maternal primary infection in the third trimester
Number of subjects: 255
Study 30596995 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI
Number of subjects: 2400
Study 30596995 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 2400
Study 30597027 — intervention group
Group type: EXPERIMENTAL
Intervention: qPCR for G. vaginalis and/or Atopobium vaginae above a threshold
Number of subjects: 120
Study 30597027 — intervention group
Group type: EXPERIMENTAL
Intervention: 16S ribosomal RNA gene sequencing
Number of subjects: 120
Study 30597027 — intervention group
Group type: EXPERIMENTAL
Intervention: High Shannon diversity index
Number of subjects: 120
Study 30597300 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample entropy (SampEn) in patients with GAD
Number of subjects: 85
Study 30597300 — intervention group
Group type: COMPARATOR
Intervention: Sample entropy (SampEn) in healthy controls (HCs)
Number of subjects: 85
Study 30597300 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship between spatial complexity and anxiety level
Number of subjects: 85
Study 30597509 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged dual anti-platelet therapy (DAPT)
Number of subjects: 16518
Study 30597509 — intervention group
Group type: COMPARATOR
Intervention: Shorter duration DAPT
Number of subjects: 16518
Study 30598343 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (15-minute continuous infusion of native GLP-1 (7-36) NH)
Number of subjects: 10
Study 30598343 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 10
Study 30598352 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic sarcopenia assessment using CT-derived measurement of T12-level muscle area.
Number of subjects: 147
Study 30598352 — intervention group
Group type: COMPARATOR
Intervention: Psoas sarcopenia measured at the L3 level using standard methods.
Number of subjects: 147
Study 30598488 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid organ transplantation
Number of subjects: 0
Study 30598500 — intervention group
Group type: EXPERIMENTAL
Intervention: TKM-080301 (0.3 mg/kg to 0.75 mg/kg, maximum tolerated dose redefined at 0.6 mg/kg)
Number of subjects: 43
Study 30598500 — intervention group
Group type: EXPERIMENTAL
Intervention: TKM-080301
Number of subjects: 43
Study 30598500 — intervention group
Group type: COMPARATOR
Intervention: Historical control
Number of subjects: 43
Study 30598642 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg-equivalent dose regimens
Number of subjects: 500
Study 30598642 — intervention group
Group type: COMPARATOR
Intervention: Standard anticoagulation
Number of subjects: 500
Study 30598669 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrolled individuals who signed a consent form and participated in the study.
Number of subjects: 863
Study 30598669 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who declined consent after one or two years of enrollment.
Number of subjects: 863
Study 30598669 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who refused specific procedures despite willingness to continue in the study.
Number of subjects: 863
Study 30598669 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who refused blood tests due to fear.
Number of subjects: 863
Study 30598669 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who declined complimentary exams.
Number of subjects: 863
Study 30598732 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of denture cleaning
Number of subjects: 0
Study 30598732 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30598833 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention for Loneliness (PAIL)
Number of subjects: 0
Study 30598833 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 30599768 — intervention group
Group type: COMPARATOR
Intervention: Plasma TMAO levels in patients with plaque rupture (3.33 μM; interquartile range: 2.48-4.57)
Number of subjects: 211
Study 30599768 — intervention group
Group type: COMPARATOR
Intervention: Elevated TMAO levels
Number of subjects: 211
Study 30599768 — intervention group
Group type: COMPARATOR
Intervention: TMAO at a cutoff level of 1.95 μM
Number of subjects: 211
Study 30600268 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic sequencing
Number of subjects: 0
Study 30600268 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrier status information return policies
Number of subjects: 0
Study 30600272 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic rapid genome sequencing
Number of subjects: 21
Study 30600393 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-foot-up-and-go test (8-FUGT)
Number of subjects: 34
Study 30600654 — intervention group
Group type: EXPERIMENTAL
Intervention: Live zoster vaccine administered at 6-12 months after zoster illness
Number of subjects: 0
Study 30600654 — intervention group
Group type: EXPERIMENTAL
Intervention: Live zoster vaccine administered at 1-5 years after zoster illness
Number of subjects: 0
Study 30600654 — intervention group
Group type: EXPERIMENTAL
Intervention: Live zoster vaccine
Number of subjects: 0
Study 30601986 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified dairy foods
Number of subjects: 904
Study 30601986 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 904
Study 30601986 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dairy
Number of subjects: 904
Study 30601986 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid dairy
Number of subjects: 904
Study 30601986 — intervention group
Group type: COMPARATOR
Intervention: Dairy intakes
Number of subjects: 904
Study 30602434 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based exercise intervention for 8 weeks
Number of subjects: 44
Study 30602433 — intervention group
Group type: EXPERIMENTAL
Intervention: We Prevent intervention (two telehealth-delivered sessions: relationship skills session and CHTC session)
Number of subjects: 0
Study 30602433 — intervention group
Group type: COMPARATOR
Intervention: Control group (one session only - CHTC session delivered via telehealth)
Number of subjects: 0
Study 30602433 — intervention group
Group type: EXPERIMENTAL
Intervention: We Prevent intervention
Number of subjects: 0
Study 30602513 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring (VR) used continuously for 14 days
Number of subjects: 16
Study 30602513 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring (VR)
Number of subjects: 16
Study 30602590 — intervention group
Group type: EXPERIMENTAL
Intervention: CT examinations for abdomen
Number of subjects: 2000000
Study 30602590 — intervention group
Group type: EXPERIMENTAL
Intervention: CT examinations for chest
Number of subjects: 2000000
Study 30602590 — intervention group
Group type: EXPERIMENTAL
Intervention: CT examinations for combined chest and abdomen
Number of subjects: 2000000
Study 30602590 — intervention group
Group type: EXPERIMENTAL
Intervention: CT examinations for head
Number of subjects: 2000000
Study 30602615 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus Docetaxel and Gemcitabine
Number of subjects: 13
Study 30602785 — intervention group
Group type: EXPERIMENTAL
Intervention: Free recall drawing task
Number of subjects: 0
Study 30602785 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual saliency and meaning maps
Number of subjects: 0
Study 30602785 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall performance
Number of subjects: 0
Study 30603376 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (23vPPV) during pregnancy
Number of subjects: 100
Study 30603376 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 100
Study 30603378 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone as adjunctive treatment
Number of subjects: 300
Study 30603378 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 300
Study 30603797 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (150 mg or 200 mg oral twice daily) and Bevacizumab (15 mg/kg once intravenously every 3 weeks)
Number of subjects: 18
Study 30604078 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiota from SWL patients
Number of subjects: 18
Study 30604078 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut microbiota from PWL patients
Number of subjects: 18
Study 30604078 — intervention group
Group type: COMPARATOR
Intervention: Gut microbiota from NSC patients
Number of subjects: 18
Study 30604117 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing
Number of subjects: 0
Study 30604117 — intervention group
Group type: COMPARATOR
Intervention: Survey results
Number of subjects: 0
Study 30605211 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab, 10 mg/kg, every 2 weeks until disease progression, unacceptable toxic effects, or withdrawal from the study.
Number of subjects: 53
Study 30605510 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate diagnosis in a ventricular arrhythmia zone with enabled therapy
Number of subjects: 1882
Study 30605510 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate therapy
Number of subjects: 1882
Study 30605510 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate shock
Number of subjects: 1882
Study 30605510 — intervention group
Group type: EXPERIMENTAL
Intervention: First 4 months following implantation
Number of subjects: 1882
Study 30605510 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay to next patient contact (DNPC)
Number of subjects: 1882
Study 30605510 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate diagnosis recurrence
Number of subjects: 1882
Study 30605510 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate therapy recurrence
Number of subjects: 1882
Study 30605751 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 Gy × 15 fx (DL1)
Number of subjects: 24
Study 30605751 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.7 Gy × 10 fx (DL2)
Number of subjects: 24
Study 30605751 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.1 Gy × 5 fx (DL3)
Number of subjects: 24
Study 30605751 — intervention group
Group type: EXPERIMENTAL
Intervention: All dose levels (DL1, DL2, DL3)
Number of subjects: 24
Study 30605751 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-of-life questionnaires
Number of subjects: 24
Study 30605751 — intervention group
Group type: EXPERIMENTAL
Intervention: International Prostate Symptom Scores
Number of subjects: 24
Study 30606052 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor or Prasugrel
Number of subjects: 1497
Study 30606052 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1497
Study 30606138 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient ischemic attack (TIA)
Number of subjects: 577
Study 30606144 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET-CT scan
Number of subjects: 85
Study 30606165 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound score on admission
Number of subjects: 175
Study 30606165 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE II score
Number of subjects: 175
Study 30606165 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate level
Number of subjects: 175
Study 30606188 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid substitution treatment (OST)
Number of subjects: 2176
Study 30606188 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine use
Number of subjects: 2176
Study 30606188 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine use
Number of subjects: 2176
Study 30606188 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment
Number of subjects: 2176
Study 30606188 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical and mental health symptom severity, psychiatric diagnosis, and psychopharmacological medication
Number of subjects: 2176
Study 30606188 — intervention group
Group type: COMPARATOR
Intervention: General population norms
Number of subjects: 2176
Study 30606204 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole associated controlled ovarian hyperstimulation (Let-COH)
Number of subjects: 23
Study 30606204 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole associated controlled ovarian hyperstimulation (Let-COH) with GnRHa trigger
Number of subjects: 23
Study 30606204 — intervention group
Group type: COMPARATOR
Intervention: Conventional controlled ovarian hyperstimulation (COH)
Number of subjects: 23
Study 30606236 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel preparation by oral administering
Number of subjects: 96
Study 30606236 — intervention group
Group type: COMPARATOR
Intervention: Bowel preparation through mid-gut transendoscopic enteral tubing (TET)
Number of subjects: 96
Study 30607254 — intervention group
Group type: EXPERIMENTAL
Intervention: New spatial design in psychiatric inpatient care
Number of subjects: 0
Study 30607261 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment
Number of subjects: 42
Study 30607261 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-m walking test (10MWT)
Number of subjects: 42
Study 30607261 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed Up and Go (TUG)
Number of subjects: 42
Study 30607261 — intervention group
Group type: EXPERIMENTAL
Intervention: Berg Balance scale (BBS)
Number of subjects: 42
Study 30607261 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities-specific Balance Confidence scales (ABC)
Number of subjects: 42
Study 30607261 — intervention group
Group type: EXPERIMENTAL
Intervention: Freezing of Gait Questionnaire (FOGQ)
Number of subjects: 42
Study 30607261 — intervention group
Group type: EXPERIMENTAL
Intervention: Parkinson's Disease Questionnaire-39 (PDQ-39)
Number of subjects: 42
Study 30607301 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin aerosol, median 2 interventions per patient (range 1-6).
Number of subjects: 24
Study 30607301 — intervention group
Group type: EXPERIMENTAL
Intervention: PIPAC procedures (2 or more).
Number of subjects: 24
Study 30607464 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 17
Study 30607464 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 17
Study 30607466 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding mothers
Number of subjects: 33
Study 30607466 — intervention group
Group type: COMPARATOR
Intervention: Control women (bottle-feeding)
Number of subjects: 33
Study 30607466 — intervention group
Group type: COMPARATOR
Intervention: Control women
Number of subjects: 33
Study 30607629 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily with trastuzumab 2 mg/kg and paclitaxel 80 mg/m²
Number of subjects: 29
Study 30607646 — intervention group
Group type: EXPERIMENTAL
Intervention: Radionuclide imaging
Number of subjects: 34
Study 30607798 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg)
Number of subjects: 321
Study 30607806 — intervention group
Group type: EXPERIMENTAL
Intervention: Capstesia smartphone application for monitoring pulse pressure variation (PPV)
Number of subjects: 0
Study 30607806 — intervention group
Group type: COMPARATOR
Intervention: Uncalibrated pulse wave analysis monitor for monitoring stroke volume variation (SVV)
Number of subjects: 0
Study 30607889 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone continuous infusions
Number of subjects: 92
Study 30607889 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone pharmacokinetic model
Number of subjects: 92
Study 30608571 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological prosthesis
Number of subjects: 1443
Study 30608571 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical prosthesis
Number of subjects: 1443
Study 30608597 — intervention group
Group type: EXPERIMENTAL
Intervention: Total saturated fatty acids (SFAs) intake in women
Number of subjects: 14383
Study 30608597 — intervention group
Group type: EXPERIMENTAL
Intervention: Even-chain SFAs intake in women
Number of subjects: 14383
Study 30608597 — intervention group
Group type: EXPERIMENTAL
Intervention: Odd-chain SFAs intake in men
Number of subjects: 14383
Study 30608597 — intervention group
Group type: EXPERIMENTAL
Intervention: Odd-chain SFAs intake in women
Number of subjects: 14383
Study 30608597 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain SFAs intake in men
Number of subjects: 14383
Study 30608597 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing 1% of energy from unsaturated fatty acids with even-chain SFAs in men
Number of subjects: 14383
Study 30609007 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 50
Study 30609007 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 50
Study 30609276 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle tenotomy with or without PRP
Number of subjects: 74
Study 30610196 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib 36 mg/m² combined with panobinostat
Number of subjects: 32
Study 30610355 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radio(chemo)therapy
Number of subjects: 99
Study 30610355 — intervention group
Group type: COMPARATOR
Intervention: Location of the primary tumor in the oropharynx
Number of subjects: 99
Study 30610518 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized mandibular movement
Number of subjects: 0
Study 30610518 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnography
Number of subjects: 0
Study 30610518 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30610872 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurotropic drugs (including opioids, sedatives, hypnotics, antidepressants)
Number of subjects: 504
Study 30610872 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 504
Study 30610872 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 504
Study 30610872 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke severity (high NIH Stroke Scale-score)
Number of subjects: 504
Study 30610872 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary lifestyle
Number of subjects: 504
Study 30610872 — intervention group
Group type: COMPARATOR
Intervention: Neurotropic drugs or cardiovascular drugs
Number of subjects: 504
Study 30611192 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical tuberculosis treatment
Number of subjects: 654
Study 30611192 — intervention group
Group type: COMPARATOR
Intervention: Active tuberculosis treatment
Number of subjects: 654
Study 30611197 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced anaesthesia (desflurane + remifentanil)
Number of subjects: 40
Study 30611197 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anaesthesia (TIVA, propofol + remifentanil)
Number of subjects: 40